ATYPICAL ANTIPSYCHOTICS USE IN CHILDREN AND ADOLESCENTS

  • Nataša Potočnik-Dajčman Zdravstveni dom dr. Adolfa Drolca Pedopsihiatrični dispanzer Vošnjakova 4 2000 Maribor
  • Hojka Gregorič-Kumperščak Klinični oddelek za pediatrijo Splošna bolnišnica Maribor Ljubljanska 5 2000 Maribor
Keywords: atypical antipsychotics, children, adolescents, shizophrenia, pervasive developmental disorders

Abstract

Background. Classical antipsychotics – neuroleptics are one of the most frequently prescribed psychotropic drugs in child psychiatry. Atypical antipsychotics are used for the same indications – psychotic (schizophrenia) as well as unpsychotic disorders (pervasive developmental disorders, mood disorders, conduct disorders and tics disorders). It is surprising that the studies on their use with regard to this age group are rather rare. They are carried out on a small number of samples and only exceptionally double blind. This article summarizes published clinical experience with atypical antipsychotics in children and adolescents. A short overview of pharmacodynamics, pharmacokinetics and side effects is given. Schizophrenia and pervasive developmental disorders are major indications for use of atypical antipsychotics in children and adolescents, but they have also been successfully used for other disorders such as aggressive behaviour, tics and anorexia nervosa.

Conclusions. With better side-effect profile, some of the atypical antipsychotics are expected to be doctrinally recognised as the first-line treatment for childhood schizophrenia and pervasive developmental disorders. However, more long-term studies carried out on a larger sample are needed. Atypical antipsychotics are already used in everyday practice as first-line treatment of childhood and adolescents schizophrenia.

Downloads

Download data is not yet available.

References

Kores-Plesničar B. Najpogosteje uporabljene skupine zdravil. In: Tomori M, Ziherl S eds. Psihiatrija. Ljubljana: Litterapicta: Medicinska fakulteta, 1999: 422–71.

Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E. Atypische Neuroleptika in der Kinder- und Jugendpsychiatrie. Z Kinder-Jugendpsychiatr 2000; 28: 45–57.

Clark AF, Lewis SW. Practitioner review: Treatment of shizophrenia in childhood and adolescence. J Child Psychol Psychiat 1998; 39: 1071–81.

Scahill L, Lynch KA. Atypical neuroleptics in children and adolescents. J Child Adolesc Psych Nursing 1998; 11: 38–42.

Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatric Services 1999; 50: 171–4.

Kaplan PM, Sadock VA. Biological therapies. In: Synopsis of psychiatry. 8th ed. Baltimore: Williams & Wilkins, 1998: 1019–91.

Clark AF, Lewis SW. Practitioner review: Treatment of shizophrenia in childhood and adolescence. J Child Psychol Psychiat 1998; 39: 1071–81.

Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolescent Psychopharmacol 1998; 8: 107–13.

Lewis R. Typical and atypical antipsychotics in adolescent shizophrenia. Can J Psychiatry 1998; 43: 596–604.

Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry 1998; 59: 644–56.

Findling RL, Grcevch SJ, Lopez I, Shulz SC. Antipsychotic medications in children and adolescents. J Clin Psychiatry 1996; 57: 19–23.

Clark AF, Shon WL. Practitioner review: Treatment of schizophrenia in childhood and adolescence. J Child Psychol Psychiat 1998; 39: 1071–81.

Campbell M, Rapaport JL, Simpson GM. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 537–45.

Walsh KH, McDougle CJ. SSRIs in children and adolescent: Research in autism, selective mutism and Prader-Willi syndrom. International Drug Therapy Newsletter 1999; 34: 89–96.

Jensen PS, Vinod SB, Vitiello B et al. Psychoactive medication prescribing practices for U. S. children: Gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999; 38: 557–65.

Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37: 372–6.

Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997; 36: 1166–7.

Paci C, D’Andreamatteo TA et al. Olanzapine in severe Gilles de la Tourette syndrome: A 52-weeks double blind crossover study versus low dose pimozide. J Neural Transmission 2000; 107: XXXIX.

Frazier JA, Biederman J, Jacobs TG et al. Olanzapine in the treatment of bipolar disorder in juveniles. The tenth biennial winter workshop on shizophrenia. Davos, 2000.

Buitelaar JK. Opel-label treatment with risperidone of 26 psychiatricallyhospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolescent Psychopharmacol 2000; 10: 19–26.

La Via MC, Gray N, Kaye H. Case reports of olanzapine treatment of anorexiy nevrosa. J Eat Disord 2000; 27: 363–6.

How to Cite
1.
Potočnik-Dajčman N, Gregorič-Kumperščak H. ATYPICAL ANTIPSYCHOTICS USE IN CHILDREN AND ADOLESCENTS. ZdravVestn [Internet]. 1 [cited 26Mar.2019];71(6). Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/1601
Section
Review